The stock price of Xilio Therapeutics Inc (NASDAQ: XLO) has jumped by 6.45 compared to previous close of 0.71. Despite this, the company has seen a gain of 11.46% in its stock price over the last five trading days. globenewswire.com reported 2025-04-04 that WALTHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2025, the company granted non-qualified stock options to purchase an aggregate of 22,900 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
Is It Worth Investing in Xilio Therapeutics Inc (NASDAQ: XLO) Right Now?
The 36-month beta value for XLO is at -0.23. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for XLO is 16.59M, and currently, shorts hold a 3.89% of that float. The average trading volume for XLO on April 17, 2025 was 3.80M shares.
XLO’s Market Performance
XLO stock saw a decrease of 11.46% in the past week, with a monthly decline of -2.21% and a quarterly a decrease of -29.82%. The volatility ratio for the week is 7.71%, and the volatility levels for the last 30 days are 7.79% for Xilio Therapeutics Inc (XLO). The simple moving average for the past 20 days is 5.28% for XLO’s stock, with a -16.34% simple moving average for the past 200 days.
Analysts’ Opinion of XLO
Many brokerage firms have already submitted their reports for XLO stocks, with Chardan Capital Markets repeating the rating for XLO by listing it as a “Buy.” The predicted price for XLO in the upcoming period, according to Chardan Capital Markets is $7 based on the research report published on December 21, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see XLO reach a price target of $36. The rating they have provided for XLO stocks is “Buy” according to the report published on January 10th, 2022.
Raymond James gave a rating of “Outperform” to XLO, setting the target price at $31 in the report published on November 16th of the previous year.
XLO Trading at -8.74% from the 50-Day Moving Average
After a stumble in the market that brought XLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.42% of loss for the given period.
Volatility was left at 7.79%, however, over the last 30 days, the volatility rate increased by 7.71%, as shares sank -4.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.66% upper at present.
During the last 5 trading sessions, XLO rose by +11.46%, which changed the moving average for the period of 200-days by -20.01% in comparison to the 20-day moving average, which settled at $0.7201. In addition, Xilio Therapeutics Inc saw -20.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XLO starting from Frankenfield Christopher James, who sale 6,954 shares at the price of $0.98 back on Jan 02 ’25. After this action, Frankenfield Christopher James now owns 12,421 shares of Xilio Therapeutics Inc, valued at $6,841 using the latest closing price.
Brennan Kevin M., the SVP, FINANCE AND ACCOUNTING of Xilio Therapeutics Inc, sale 1,803 shares at $0.98 during a trade that took place back on Jan 02 ’25, which means that Brennan Kevin M. is holding 3,197 shares at $1,774 based on the most recent closing price.
Stock Fundamentals for XLO
Current profitability levels for the company are sitting at:
- -9.4 for the present operating margin
- 0.86 for the gross margin
The net margin for Xilio Therapeutics Inc stands at -9.18. The total capital return value is set at -1.36. Equity return is now at value -214.02, with -88.24 for asset returns.
Based on Xilio Therapeutics Inc (XLO), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at -2.26.
Currently, EBITDA for the company is -58.0 million with net debt to EBITDA at 0.81. When we switch over and look at the enterprise to sales, we see a ratio of -1.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.21.
Conclusion
In conclusion, Xilio Therapeutics Inc (XLO) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
